Edesa Biotech Surges 32.78% on Paridiprubart Data Presentation Plans
EDSA•Shares of Edesa Biotech jumped 32.78% on volume exceeding 1 million shares after the company announced plans to present new paridiprubart data. The antibody therapy for Acute Kidney Injury will be showcased at the European Renal Association Congress, marking a key clinical development milestone.
1. Stock Rally Driven by Clinical Catalyst
Edesa Biotech shares soared 32.78% to close at $11.95, trading between $9.48 and $12.50 on volume exceeding 1 million shares. Investor interest was spurred by anticipation of new clinical data presentations, driving unusually high turnover for the small-cap stock.
2. Paridiprubart Data Presentation Details
The company will present data on its lead antibody therapy, paridiprubart, targeting Acute Kidney Injury at the European Renal Association Congress. This event highlights progress in Edesa’s clinical pipeline and could influence regulatory and commercial prospects for the drug.
